Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.74)
# 3,367
Out of 5,154 analysts
58
Total ratings
41.86%
Success rate
-1.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $28.78 | +14.66% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $93.52 | +67.88% | 11 | Dec 12, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $33.19 | -9.61% | 6 | Oct 21, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.53 | -34.64% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $29.27 | -24.84% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $8.17 | +83.60% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.54 | +267.23% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $28.33 | -1.16% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.48 | +4,224.32% | 6 | Aug 15, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Buy | $25 → $21 | $3.06 | +586.27% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $42.82 | -67.31% | 2 | Dec 20, 2022 |
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $28.78
Upside: +14.66%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $93.52
Upside: +67.88%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $33.19
Upside: -9.61%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.53
Upside: -34.64%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $29.27
Upside: -24.84%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $8.17
Upside: +83.60%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.54
Upside: +267.23%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $28.33
Upside: -1.16%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.48
Upside: +4,224.32%
Aclaris Therapeutics
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.06
Upside: +586.27%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $42.82
Upside: -67.31%